Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.

ABSTRACT: Vi capsular polysaccharide (Vi) conjugate vaccines, which can prevent typhoid in infants and young children, are being developed. Comparative immunogenicity studies are facilitated by an International Standard (IS) for human anti-Vi IgG. 16/138, a pool of sera from volunteers which received either Vi conjugate vaccine or plain Vi vaccine, was assessed as an IS alongside U.S. reference reagent Vi-IgG_{R1, 2011}. Samples were tested in a commercial ELISA (n = 7), a standardised ELISA based on biotinylated Vi (n = 7) and in-house ELISAs (n = 7). Valid estimates were obtained for the potency of all samples in the commercial ELISA, and the commutability of 16/138 and Vi-IgG_{R1, 2011} was evident for the commercial ELISA and in-house ELISAs based on a coating of Vi and protein.

SUBMITTER: Rijpkema S 

PROVIDER: S-EPMC6238147 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature